Acumen Pharmaceuticals (ABOS) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 3, 2026, to be held virtually for stockholders of record as of April 8, 2026.

• Proxy materials, including the proxy statement and annual report, are available online, with paper copies available upon request by May 25, 2026.

Voting matters and shareholder proposals

• Election of three Class II directors to serve until the 2029 annual meeting: George Golumbeski, Ph.D., Derrell Porter, M.D., and Laura Stoppel, Ph.D.

• Ratification of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.

• Approval of the Amended and Restated 2021 Equity Incentive Plan.

• Consideration of any other business properly brought before the meeting or its adjournments.

Board of directors and corporate governance

• Board recommends voting for all director nominees, the ratification of the auditor, and the equity plan proposal.